Drop-In Replacement For CAS 144809-28-9: Pioglitazone 2-Imine Supply
Structural Pathway Divergence & Purity Grades: CAS 105355-26-8 vs CAS 144809-28-9 Synthesis Architectures
The synthesis architecture for CAS 105355-26-8 diverges from the standard benzylidene condensation route associated with CAS 144809-28-9 by implementing a controlled imine formation step that minimizes the generation of isomeric byproducts. This approach is critical when evaluating the Pioglitazone 2-Imine as a drop-in replacement, as the structural integrity of the thiazolidinedione core must remain uncompromised during the subsequent hydrogenation phase. The chemical entity, formally identified as 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]-2-imino-4-thiazolidinone, exhibits distinct stability profiles compared to the benzylidene variant. Procurement managers should note that the synthesis route for CAS 105355-26-8 allows for tighter control over the pyridine-ethoxy moiety, reducing the risk of oxidative degradation that can plague less refined intermediates. This Thiazolidinone Derivative serves as a high-performance API Precursor, ensuring that the final Pioglitazone API meets stringent pharmacopeial requirements without requiring extensive downstream purification. NINGBO INNO PHARMCHEM engineers the Pioglitazone 2-Imine (CAS 105355-26-8) to match the molecular weight and formula of CAS 144809-28-9 while optimizing the crystal lattice structure for superior flowability and reduced hygroscopicity during storage.
COA Parameters Comparison Tables: Single Impurity Limits & Trace Pyridine-Ethoxy Degradation Product Thresholds
Technical validation requires a direct comparison of critical quality attributes. The following table outlines the structural equivalence and parameter monitoring strategy. Specific numerical limits for impurities and purity must be verified against the batch-specific documentation, as these values are subject to analytical variance and regulatory updates.
| Parameter | CAS 144809-28-9 (Reference Data) | CAS 105355-26-8 (NINGBO INNO PHARMCHEM) |
|---|---|---|
| Molecular Formula | C19H18N2O3S | C19H18N2O3S |
| Molecular Weight | 354.423 g/mol | 354.42 g/mol |
| Melting Point | 156-159°C | Please refer to the batch-specific COA |
| Assay / Purity | Not Specified in Context | Please refer to the batch-specific COA |
| Related Substances | Not Specified in Context | Please refer to the batch-specific COA |
| Trace Pyridine-Ethoxy Degradation Product | Not Monitored | Monitored & Controlled per Batch COA |
Field engineering data indicates that the pyridine-ethoxy side chain is susceptible to oxidative cleavage when exposed to elevated temperatures or prolonged light exposure during intermediate storage. This degradation pathway generates a trace pyridine-ethoxy degradation product that is not typically listed on standard COAs but can significantly impact the final API color. During scale-up trials, batches containing elevated levels of this specific impurity resulted in a yellowing of the Pioglitazone API that exceeded pharmacopeial color limits, even after standard decolorization steps. NINGBO INNO PHARMCHEM implements a dedicated analytical method to quantify this degradation product, ensuring that the manufacturing process maintains thresholds low enough to prevent color drift in the final API. This proactive monitoring distinguishes our supply from generic sources that rely solely on standard HPLC purity assays.
Technical Specifications for Catalyst Longevity: Mitigating Pd/C Hydrogenation Poisoning & Scale-Up Reaction Yield Stability
The conversion of the imine intermediate to the amine via Pd/C hydrogenation is highly sensitive to catalyst poisoning. The pyridine nitrogen within the 5-ethyl-2-pyridyl group exhibits a strong affinity for palladium surfaces, which can reduce catalyst turnover numbers if the intermediate contains trace acidic impurities or halide residues. Our technical specifications for CAS 105355-26-8 focus on minimizing these catalyst poisons to ensure consistent reaction kinetics. Field experience demonstrates that intermediates with uncontrolled trace halides can cause a rapid drop in hydrogenation rate, leading to incomplete conversion and the formation of difficult-to-remove byproducts.
Furthermore, thermal management during hydrogenation is critical. When hydrogenating at temperatures exceeding 45°C, there is an increased risk of over-reduction of the pyridine ring, which compromises the pharmacological activity of the final product. NINGBO INNO PHARMCHEM's intermediate maintains structural integrity up to 60°C, providing a wider safety margin for exotherm control during large-scale batch processing. This thermal stability allows R&D chemists to optimize reaction conditions without the risk of scaffold degradation. The consistent purity profile of our Pioglitazone Intermediate ensures that catalyst loading can be optimized for cost-efficiency, reducing the overall cost of goods without sacrificing yield stability. Procurement teams should request the batch-specific COA to verify the absence of catalyst-inhibiting impurities before initiating scale-up trials.
Bulk Packaging Protocols & Supply Chain Integration: GMP-Compliant Drop-in Replacement for Pioglitazone 2-Imine
Supply chain reliability is paramount for continuous API production. NINGBO INNO PHARMCHEM provides CAS 105355-26-8 as a GMP-compliant drop-in replacement for CAS 144809-28-9, packaged to preserve chemical integrity during global transit. Standard packaging utilizes 25kg double-layer PE bags with aluminum foil lining, sealed within robust export cartons. This configuration is designed to prevent moisture ingress, which can trigger hydrolysis of the imine bond, and to block UV radiation that accelerates oxidative degradation. For larger volumes, IBC containers are available with nitrogen blanketing to maintain an inert atmosphere.
During winter transit in unheated containers, the imine moiety can undergo partial crystallization changes that affect flowability and dosing accuracy. Our packaging protocol includes thermal buffering measures to mitigate this risk, ensuring that the material remains free-flowing upon arrival. Logistics are coordinated to minimize transit time and exposure to environmental stressors. NINGBO INNO PHARMCHEM operates as a global manufacturer with established export capabilities, ensuring that quality assurance protocols are maintained from synthesis to delivery. This packaging strategy supports seamless integration into existing manufacturing workflows, eliminating the need for re-validation of handling procedures when switching from competitor sources.
Frequently Asked Questions
Can I cross-synthesize Pioglitazone from alternative thiazolidinedione scaffolds using this intermediate?
Cross-synthesis from alternative thiazolidinedione scaffolds is technically feasible but generally not recommended for commercial production due to significant yield reductions and increased impurity profiles. CAS 105355-26-8 is optimized for the direct hydrogenation pathway to Pioglitazone, ensuring high conversion rates and minimal byproduct formation. Deviating from this established route can introduce structural variations that complicate purification and may result in API specifications that fail to meet pharmacopeial standards. NINGBO INNO PHARMCHEM advises maintaining the standard synthesis architecture to preserve yield efficiency and product consistency.
What are the yield differences when switching from CAS 144809-28-9 to CAS 105355-26-8?
Switching to CAS 105355-26-8 typically results in comparable or improved yields due to the enhanced purity and stability of the intermediate. The controlled imine formation process reduces the presence of isomeric impurities that can interfere with hydrogenation, leading to more consistent reaction outcomes. Field data indicates that batches processed with our intermediate exhibit lower catalyst consumption and fewer downstream purification steps, which can improve overall process efficiency. Yield performance should be validated through pilot-scale trials using the batch-specific COA to confirm compatibility with your existing manufacturing parameters.
How do I verify COA parameters for impurity limits before placing a bulk order?
Verification of COA parameters is a standard part of our procurement process. NINGBO INNO PHARMCHEM provides detailed batch-specific COAs that include assay results, related substance profiles, and specific impurity limits. Procurement managers can request sample COAs for review prior to order confirmation. Additionally, we support third-party testing and can provide samples for independent analysis to ensure that all parameters meet your internal quality standards. Our technical support team is available to discuss specific impurity thresholds and assist with the qualification process to ensure a seamless transition to our supply.
Sourcing and Technical Support
NINGBO INNO PHARMCHEM delivers engineering-grade Pioglitazone 2-Imine with the structural precision and supply chain reliability required for modern API manufacturing. Our drop-in replacement solution eliminates the risks associated with inconsistent intermediate quality while supporting cost-efficiency through optimized catalyst usage and yield stability. Partner with a verified manufacturer. Connect with our procurement specialists to lock in your supply agreements.